Kitov Pharmaceuticals is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov’s veteran team of healthcare professionals maintains a proven track record in streamlined end-to-end drug development and approval.

Kitov’s flagship combination drug, KIT-302, aims to treat osteoarthritis pain and hypertension simultaneously. KIT-302 achieved the primary efficacy endpoint for its Phase III clinical trial. A New Drug Application (NDA) was submitted in July 2017 and the U.S. Food and Drug Administration (FDA)  filed the NDA on September 29 2017, thereby accepting the NDA for a full review.

Kitov’s newest drug, NT-219, which is developed by its majority-owned subsidiary, TyrNovo, is a small molecule that presents a new concept in cancer therapy. When combined with various approved oncology drugs, NT-219 demonstrated potent anti-tumor effects and increased survival in various cancer models.

By lowering development risk and cost through fast-track regulatory approval of novel therapeutics, Kitov plans to deliver a rapid ROI and long-term potential to investors, while making a meaningful impact on people’s lives.

Founded in 2010, Kitov became a public company in 2013 when its shares were first traded on the Tel Aviv Stock Exchange (TASE). Kitov successfully issued an IPO on NASDAQ in November 2015. The company currently trades on both stock exchanges.